Skip to main content
. Author manuscript; available in PMC: 2019 Nov 5.
Published in final edited form as: Mol Pharm. 2018 Oct 15;15(11):4933–4946. doi: 10.1021/acs.molpharmaceut.8b00579

Figure 3.

Figure 3.

Optimal ratio determination for cGAMP and resiquimod (R848) microparticles. Bone marrow derived dendritic cells from C57BL/6 mice were treated for 22 h with indicated concentrations of resiquimod (R848) and cGAMP, both of which were individually encapsulated within acetalated dextran (Ace-DEX) microparticles. Supernatants were analyzed for (A) IL-6, (B) TNF, (C) IL-1β, (D) IL-12p70, and (E) IFN-β. Data are presented as mean ± SEM (n = 4).